Correction: Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial 🔗 Access full article via Journal for ImmunoTherapy of CancerShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon